为了计算在18F-FDG亮度恶性肿瘤的M分期中，全身[18F]FDG PET/MR的总体诊断性能。进行了一项关于[18F]FDG PET/MR进行M分期的诊断性的荟萃分析，包括以下研究：(1)评估[18F]FDG PET/MR在检测远处转移中的应用；(2)将[18F]FDG PET/MR与组织病理学、随访或异步多模态成像作为参考标准进行比较；(3)提供全身评估的数据；(4)提供足够的数据计算荟萃分析的性能。使用置信区间计算总体性能。此外，还绘制了森林图、SROC曲线和似然比散点图。所有分析都是使用STATA 16进行的。从52个符合条件的研究中，共有2289名患者和2072个转移入荟聚分析。在患者和病变水平上，全身的总体灵敏度分别为0.95 (95% CI: 0.91-0.97)和0.97 (95% CI: 0.91-0.99)。总体特异性分别为0.99 (95% CI: 0.97-1.00)和0.97 (95% CI: 0.90-0.99)。另外，进行了亚组分析。肺癌、胃肠道癌、乳腺癌和妇科肿瘤的计算出的总体灵敏度分别为0.90、0.93、1.00和0.97。总体特异性分别为1.00、0.98、0.97和1.00。此外，非小细胞肺癌、结直肠癌和宫颈癌的总体灵敏度分别为0.92、0.96和0.86。总体特异性分别为1.00、0.95和1.00。[18F]FDG PET/MR是报道中在M分期中高精确度的成像技术。结果显示了在每种恶性肿瘤类型中的高灵敏度和特异性。因此，我们的发现可能有助于临床医生和患者对[18F]FDG PET/MR在临床中的性能充满信心。尽管18F-FDG PET/MR目前不是常规的成像技术 根据当前指南，这主要是因为其可用性和后勤问题所致，但我们的研究结果可能为其性能的证据之限制提供补充，显示了95%的灵敏度和97%的特异性。•整个身体的[18F]FDG PET/MR在患者和病变水平上显示出高准确性，可用于检测远处转移。•在患者和病变水平上的总体灵敏度分别为95％和97％，总体特异性分别为99％和97％。•结果表明，18F-FDG PET/MR对于排除和确认远处转移是一种强有力的成像技术。© 2023. 作者(们)在欧洲放射学协会的独家授权下。

To calculate the pooled diagnostic performances of whole-body [18F]FDG PET/MR in M staging of [18F]FDG-avid cancer entities.A diagnostic meta-analysis was conducted on the [18F]FDG PET/MR in M staging, including studies: (1) evaluated [18F]FDG PET/MR in detecting distant metastasis; (2) compared[ 18F]FDG PET/MR with histopathology, follow-up, or asynchronous multimodality imaging as the reference standard; (3) provided data for the whole-body evaluation; (4) provided adequate data to calculate the meta-analytic performances. Pooled performances were calculated with their confidence interval. In addition, forest plots, SROC curves, and likelihood ratio scatterplots were drawn. All analyses were performed using STATA 16.From 52 eligible studies, 2289 patients and 2072 metastases were entered in the meta-analysis. The whole-body pooled sensitivities were 0.95 (95%CI: 0.91-0.97) and 0.97 (95%CI: 0.91-0.99) at the patient and lesion levels, respectively. The pooled specificities were 0.99 (95%CI: 0.97-1.00) and 0.97 (95%CI: 0.90-0.99), respectively. Additionally, subgroup analyses were performed. The calculated pooled sensitivities for lung, gastrointestinal, breast, and gynecological cancers were 0.90, 0.93, 1.00, and 0.97, respectively. The pooled specificities were 1.00, 0.98, 0.97, and 1.00, respectively. Furthermore, the pooled sensitivities for non-small cell lung, colorectal, and cervical cancers were 0.92, 0.96, and 0.86, respectively. The pooled specificities were 1.00, 0.95, and 1.00, respectively.[18F]FDG PET/MR was a highly accurate modality in M staging in the reported [18F]FDG-avid malignancies. The results showed high sensitivity and specificity in each reviewed malignancy type. Thus, our findings may help clinicians and patients to be confident about the performance of [18F]FDG PET/MR in the clinic.Although [18F]FDG PET/MR is not a routine imaging technique in current guidelines, mostly due to its availability and logistic issues, our findings might add to the limited evidence regarding its performance, showing a sensitivity of 0.95 and specificity of 0.97.• The whole-body [18F]FDG PET/MR showed high accuracy in detecting distant metastases at both patient and lesion levels. • The pooled sensitivities were 95% and 97% and pooled specificities were 99% and 97% at patient and lesion levels, respectively. • The results suggested that 18F-FDG PET/MR was a strong modality in the exclusion and confirmation of distant metastases.© 2023. The Author(s), under exclusive licence to European Society of Radiology.